An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)

Research summary

This extension trial, 1305-0031, is aimed to assess the tolerability, long-term safety, and efficacy of BI 1015550 in patients with IPF and PPF over a longer duration of treatment. This will also fulfil a commitment to patients and the medical community to continue to provide a (potentially) beneficial treatment to trial participants after the end of their involvement in pivotal trials 1305-0014 and 1305-0023, which is important considering the progressive nature of IPF and PPF and the continuing unmet medical need in these patients.

Principal Investigator

Dr Rachel Hoyles

Contact us

Email: samantha.chilcott@ndm.ox.ac.uk

IRAS number

1009187